Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04524871
Registration number
NCT04524871
Ethics application status
Date submitted
21/08/2020
Date registered
24/08/2020
Date last updated
3/06/2024
Titles & IDs
Public title
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Query!
Scientific title
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Query!
Secondary ID [1]
0
0
GO42216
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Liver Cancers
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Liver
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Bevacizumab 15 mg/kg
Treatment: Drugs - Tiragolumab
Treatment: Drugs - Tocilizumab
Treatment: Drugs - TPST-1120
Treatment: Drugs - Tobemstomig 2100 mg
Treatment: Drugs - Bevacizumab 10 mg/kg
Treatment: Drugs - Tobemstomig 600 mg
Treatment: Drugs - Tobemstomig 1200 mg dose
Treatment: Drugs - ADG126
Treatment: Drugs - IO-108
Treatment: Drugs - NKT2152
Active Comparator: Stage 1: Atezolizumab + Bevacizumab - Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + Tiragolumab - Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + Tocilizumab - Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + TPST-1120 - Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Tobemstomig 2100 mg Q2W + Bevacizumab - Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Tobemstomig 600 mg Q3W + Bevacizumab - Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Tobemstomig 1200 mg Q3W + Bevacizumab - Participants will receive Tobemstomig plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + ADG126 - Participants will receive atezolizumab plus bevacizumab plus ADG126 until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + IO-108 - Participants will receive atezolizumab plus bevacizumab plus IO-108 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Experimental: Stage 1: Atezolizumab + Bevacizumab + NKT2152 - Participants will receive atezolizumab plus bevacizumab plus NKT2152 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
Treatment: Drugs: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
Treatment: Drugs: Bevacizumab 15 mg/kg
Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Treatment: Drugs: Tiragolumab
Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Treatment: Drugs: Tocilizumab
Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
Treatment: Drugs: TPST-1120
TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
Treatment: Drugs: Tobemstomig 2100 mg
Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
Treatment: Drugs: Bevacizumab 10 mg/kg
Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
Treatment: Drugs: Tobemstomig 600 mg
Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Treatment: Drugs: Tobemstomig 1200 mg dose
Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
Treatment: Drugs: ADG126
ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
Treatment: Drugs: IO-108
IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
Treatment: Drugs: NKT2152
NKT2152 will be administered at a dose of 200 mg by mouth once daily x 14 days (loading) then 50 mg once daily (maintenance) on Days 15-21 during the first cycle. For all subsequent cycles, NKT2152 is administered at 50 mg once daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR, defined as the proportion of participants with a complete response or partial response on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.
Query!
Timepoint [1]
0
0
From randomization until disease progression or loss of clinical benefit (up to approximately 7-9 years)
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.
Query!
Timepoint [1]
0
0
Randomization to first occurrence of disease progression or death from any cause in Stage 1 (up to approximately 7-9 years)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS after randomization, defined as the time from randomization to death from any cause.
Query!
Timepoint [2]
0
0
Randomization to death from any cause (up to approximately 7-9 years)
Query!
Secondary outcome [3]
0
0
OS at Specific Timepoints
Query!
Assessment method [3]
0
0
OS at a specific timepoint, such as Month 6
Query!
Timepoint [3]
0
0
Randomization to a specific timepoint, such as Month 6
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR)
Query!
Assessment method [4]
0
0
DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1.
Query!
Timepoint [4]
0
0
First occurrence of a documented objective response to disease progression or death (up to approximately 7-9 years)
Query!
Secondary outcome [5]
0
0
Disease Control
Query!
Assessment method [5]
0
0
Disease control, defined as stable disease for >=12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.
Query!
Timepoint [5]
0
0
Randomization to end of study (approximately 7-9 years)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Adverse Events During Stage 1
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline through the end of the study (approximately 7-9 years)
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Adverse Events During Stage 2
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline through the end of the study (approximately 7-9 years)
Query!
Eligibility
Key inclusion criteria
Stage 1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days
prior to randomization
- Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with
diagnosis confirmed by histology/cytology or clinically by American Association for
the Study of
- Liver Diseases criteria in cirrhotic patients
- Child-Pugh class A within 7 days prior to randomization
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment for HCC
- Life expectancy >= 3 months
- Availability of a representative tumor specimen that is suitable for determination of
PD-L1 and/or additional biomarker status via central testing
Stage 1 and Stage 2
- Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
- Adequate hematologic and end-organ function within 7 days prior to initiation of study
treatment
- Documented virology status of hepatitis, as confirmed by screening tests for hepatitis
B virus - (HBV) and hepatitis C virus (HCV)
- Negative HIV test at screening
- For women of childbearing potential: agreement to remain abstinent or use
contraception and for men: agreement to remain abstinent or use contraception, and
agreement to refrain from donating sperm
Stage 2
- ECOG Performance Status of 0, 1, or 2
- Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable
toxicity not related to atezolizumab or RO7247669 or loss of clinical benefit as
determined by the investigator while receiving Stage 1 treatment
- Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage
1 (if deemed clinically feasible)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Stage 1
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies or
inhibitors targeting HIF2a
- Treatment with investigational therapy within 28 days prior to initiation of study
- Treatment with locoregional therapy to liver within 28 days prior to initiation of
study, or non-recovery from side effects of any such procedure
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or
at high risk for bleeding
- Prior bleeding event due to esophageal and/or gastric varices within 6 months prior to
initiation of study
- AEs from prior anti-cancer therapy that have not resolved to Grade <= 1 or better,
with the exception of alopecia of any grade
- Inadequately controlled hypertension
- History of hypertensive crisis or hypertensive encephalopathy
- Significant vascular disease
- History of hemoptysis within 1 month prior to initiation of study
- Evidence of bleeding diathesis or significant coagulopathy
- Current or recent use of asprin (>325 mg/day) or treatment with clopidogrel,
dipyramidole, ticlopidine, or cilostazol
- Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic
agents for therapeutic (as opposed to prophylactic) purpose
- Core biopsy or other minor surgical procedure within 3 days prior to initiation of
study
- History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal
abscess, intestinal obstruction and/or clinical signs/symptoms of GI obstruction
- Evidence of abdominal free air not explained by paracentesis or recent surgery
- Serious, non-healing/dehiscing wound, active ulcer, or untreated bone fracture
- Grade >=2 proteinuria
- Metastatic disease involving major airways/blood vessels, or centrally located
mediastinal tumor masses of large volume
- History of clinically significant intra-abdominal inflammatory process
- Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to
initiation of study with the exception of palliative radiotherapy to bone lesions
within 7 days prior to initiation of study
- Major surgery, open biopsy, or significant traumatic injury within 28 days prior to
initiation of study; or abdominal surgery, abdominal interventions or significant
abdominal traumatic injury within 60 days prior to initiation of study; or
anticipation of need for major surgery during study or non-recovery from side effects
of any such procedure
- Chronic daily treatment with NSAID
- Eligible only for control arm
Stage 1 and 2
- Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- History of hepatic encephalopathy
- Moderate or severe ascites
- HBV and HCV coinfection
- Symptomatic, untreated, or actively progressing CNS metastases
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
drainage procedures
- Uncontrolled or symptomatic hypercalcemia
- Active or history of autoimmune disease or immune deficiency
- History of IPF, organizing pneumonia, drug-induced or idiopathic pneumonitis, or
evidence of active pneumonitis on screening chest CT scan
- Active TB
- Significant CV disease within 3 months prior to initiation of study, unstable
arrhythmia, or unstable angina
- Major surgery, other than for diagnosis, within 4 weeks prior to initiation of study,
or anticipated major surgery during study
- History of malignancy other than HCC within 5 years prior to screening
- Severe infection within 4 weeks prior to initiation of study
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation
of study
- Prior allogeneic stem cell or solid organ transplantation
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study,
or anticipation of need for such a vaccine during atezolizumab treatment or within 5
months after the final dose of atezolizumab
- History of severe allergic anaphylactic reactions to chimeric or humanized antibodies
or fusion proteins
- Known allergy or hypersensitivity to any of the study drugs or any of their excipients
Treatment with systemic immunostimulatory, immunosuppressive agents within 4 weeks or
5 drug-elimination half-lives (whichever is longer) prior to initiation of study
- Treatment with systemic immunosuppressive medication within 2 weeks prior to
initiation of study
- Patients entering Stage 2: immunotherapy-related adverse events that have not resolved
to Grade 1 or better or to baseline at time of consent
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
2/11/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/08/2026
Query!
Actual
Query!
Sample size
Target
506
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Tennessee
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Beijing
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Shanghai
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Dijon
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Marseille CEDEX 05
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Rennes
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Villejuif
Query!
Country [12]
0
0
Israel
Query!
State/province [12]
0
0
Haifa
Query!
Country [13]
0
0
Israel
Query!
State/province [13]
0
0
Jerusalem
Query!
Country [14]
0
0
Israel
Query!
State/province [14]
0
0
Petach Tikva
Query!
Country [15]
0
0
Israel
Query!
State/province [15]
0
0
Tel-Aviv
Query!
Country [16]
0
0
Korea, Republic of
Query!
State/province [16]
0
0
Seoul
Query!
Country [17]
0
0
New Zealand
Query!
State/province [17]
0
0
Auckland
Query!
Country [18]
0
0
Taiwan
Query!
State/province [18]
0
0
Tainan
Query!
Country [19]
0
0
Taiwan
Query!
State/province [19]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Adagene Inc
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
Tempest Therapeutics
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Commercial sector/Industry
Query!
Name [3]
0
0
NiKang Therapeutics, Inc.
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Commercial sector/Industry
Query!
Name [4]
0
0
Immune-Onc Therapeutics
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants
with advanced liver cancers. The study is designed with the flexibility to open new treatment
arms as new treatments become available, close existing treatment arms that demonstrate
minimal clinical activity or unacceptable toxicity, modify the participant population, or
introduce additional cohorts of participants with other types of advanced primary liver
cancer.
Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular
carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible
participants will initially be randomly assigned to one of several treatment arms (Stage 1).
Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1
may be eligible to receive treatment with a different treatment combination (Stage 2). When a
Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04524871
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Reference Study ID Number: GO42216 https://forpatients.roche.com/
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-662-6728 (U.S. and Canada)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04524871
Download to PDF